Dako and Amgen to collaborate on companion cancer diagnostic

Dako has entered into a development and collaboration agreement with Amgen to develop a diagnostic test for an Amgen cancer drug candidate targeted for an undisclosed rare and deadly cancer. The agreement marks the continuation of Dako's plan to advance companion diagnostics by collaborating with partners in the pharmaceutical sector. Over the past two years, Dako has signed agreements with AstraZeneca, Bristol-Myers Squibb and Genentech in the field.

This article is tagged to:
Sector: Medical Devices
Geography: Denmark

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.